Seven Eight Capital, LP Revance Therapeutics, Inc. Transaction History

Seven Eight Capital, LP

  • $1.05 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023
BUY
$24.7 - $37.61 $1.53 Million - $2.32 Million
61,788 Added 693.55%
70,697 $1.79 Million
Q1 2023

May 12, 2023
BUY
$18.36 - $35.27 $163,569 - $314,220
8,909 New
8,909 $286,000
Q2 2020

Aug 06, 2020
SELL
$12.6 - $26.55 $142,241 - $299,722
-11,289 Closed
0 $0
Q1 2020

May 14, 2020
BUY
$12.46 - $27.81 $140,660 - $313,947
11,289 New
11,289 $167,000

Others Institutions Holding RVNC

# of Institutions
234
Shares Held
82.8M
Call Options Held
680K
Put Options Held
896K
View Full List

About Revance Therapeutics, Inc.

RVNC Quotes by TradingView
  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Seven Eight Capital, LP Portfolio

Follow Seven Eight Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Seven Eight Capital, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email